The Experts below are selected from a list of 10839 Experts worldwide ranked by ideXlab platform
Antoine Hadengue - One of the best experts on this subject based on the ideXlab platform.
-
Biliary migration of hepatocellular carcinoma fragment after Transcatheter Arterial Chemoembolization therapy.
European journal of gastroenterology & hepatology, 2000Co-Authors: Laurent Spahr, Jean-louis Frossard, Christian Felley, Marie-anne Brundler, Pietro Majno, Antoine HadengueAbstract:Occasional side-effects of Transcatheter Arterial Chemoembolization therapy in hepatocellular carcinoma are essentially related to tissue necrosis. We report the case of a patient with hepatocellular carcinoma who experienced an acute common bile duct obstruction a few weeks after such a procedure, in the absence of obvious biliary tract invasion. An endoscopic sphincterotomy relieved the obstruction. At histology, the intra-biliary material was identified as a fragment of hepatocellular carcinoma. We discuss the causes of obstructive jaundice in the setting of hepatocellular carcinoma as well as in the specific situation of Transcatheter Arterial Chemoembolization therapy.
Wei Wei - One of the best experts on this subject based on the ideXlab platform.
-
The clinical efficacy and safety of Transcatheter Arterial Chemoembolization combined with sorafenib in the treatment of large hepatocellular carcinoma
Journal of Modern Oncology, 2016Co-Authors: Wei Wei, Yi Changhong, Chen Huabing, Liu SibinAbstract:Objective:To study the clinical efficacy and safety of Transcatheter Arterial Chemoembolization com-bined sorafenib in the treatment of large hepatocellular carcinoma.Methods:Retrospectively analyse the clinical data of 85 cases of patients with large hepatocellular carcinoma(diameter≥10cm)from June 2009 -June 2013,including 26 patients received Transcatheter Arterial Chemoembolization combined with sorafenib therapy as observation group,37 patients received the Transcatheter Arterial Chemoembolization therapy as control group 1,22 patients received the sor-afenib therapy as control group 2.Kaplan -Meier method was used to draw the survival curves.The median survival time,survival rate,the median tumor progress time of the three groups using the Log -rank test were compared and the incidence of adverse reactions of the three groups were observed.Results:The median survival time of the observa-tion group,control group 1 and group 2 respectively was 16.3 months(95%CI:10.1 ~22.3 months),10.4 months (95%CI:7.2 ~13.5 months),and 6.2 months(95%CI:4.2 ~5.6 months)(P 0.05 ).Conclusion:Transcatheter Arterial Chemoembolization combined with sorafenib in treatment of large hepatocellular carcinoma can delay the tumor progression,prolong the survival period,and have the well safety tolerance,which has a good prospect of clinical application.
-
Hepatic resection versus Transcatheter Arterial Chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
Japanese journal of clinical oncology, 2015Co-Authors: Yong Fa Zhang, Wei Wei, Zhi Xing Guo, Jia Hong Wang, Ming Shi, Rong Ping GuoAbstract:Objective: To compare the outcomes of hepatic resection and Transcatheter Arterial Chemoembolization for resectable hepatocellular carcinoma with hepatic vein tumor thrombus. Methods: From January 2006 to November 2013, 28 patients initially diagnosed with resectable hepatocellular carcinoma combined with hepatic vein tumor thrombus received hepatic resection. These patients were compared with 56 case-matched controls (1:2 ratio) selected from a pool of 91 patients who received Transcatheter Arterial Chemoembolization as an initial treatment during the same period. Clinical characteristics, adverse events, overall survival and survival-related factors were analyzed. Results: The 1-, 2- and 3-year overall survival rates were 66.5, 37.4 and 28.5% for the hepatic resection group and 32.3, 18.7 and 15.6% for the Transcatheter Arterial Chemoembolization group (P = 0.015), respectively. No significant difference was found between the two groups in terms of complications and mortality. Multivariate analyses revealed combined portal vein tumor thrombosis (HR = 2.116; 95% CI: 1.26–3.57; P = 0.005) and treatment allocation (hepatic resection = 2.289; 95% CI, 1.30–4.02; P= 0.004) as risk factors for overall survival. Conclusions: Hepatic resection provides a good prognosis for hepatocellular carcinoma patients with hepatic vein tumor thrombus compared with patients undergoing Transcatheter Arterial Chemoembolization, and the most important factor related to survival was co-existence with portal vein invasion.
Liu Sibin - One of the best experts on this subject based on the ideXlab platform.
-
The clinical efficacy and safety of Transcatheter Arterial Chemoembolization combined with sorafenib in the treatment of large hepatocellular carcinoma
Journal of Modern Oncology, 2016Co-Authors: Wei Wei, Yi Changhong, Chen Huabing, Liu SibinAbstract:Objective:To study the clinical efficacy and safety of Transcatheter Arterial Chemoembolization com-bined sorafenib in the treatment of large hepatocellular carcinoma.Methods:Retrospectively analyse the clinical data of 85 cases of patients with large hepatocellular carcinoma(diameter≥10cm)from June 2009 -June 2013,including 26 patients received Transcatheter Arterial Chemoembolization combined with sorafenib therapy as observation group,37 patients received the Transcatheter Arterial Chemoembolization therapy as control group 1,22 patients received the sor-afenib therapy as control group 2.Kaplan -Meier method was used to draw the survival curves.The median survival time,survival rate,the median tumor progress time of the three groups using the Log -rank test were compared and the incidence of adverse reactions of the three groups were observed.Results:The median survival time of the observa-tion group,control group 1 and group 2 respectively was 16.3 months(95%CI:10.1 ~22.3 months),10.4 months (95%CI:7.2 ~13.5 months),and 6.2 months(95%CI:4.2 ~5.6 months)(P 0.05 ).Conclusion:Transcatheter Arterial Chemoembolization combined with sorafenib in treatment of large hepatocellular carcinoma can delay the tumor progression,prolong the survival period,and have the well safety tolerance,which has a good prospect of clinical application.
Laurent Spahr - One of the best experts on this subject based on the ideXlab platform.
-
Biliary migration of hepatocellular carcinoma fragment after Transcatheter Arterial Chemoembolization therapy.
European journal of gastroenterology & hepatology, 2000Co-Authors: Laurent Spahr, Jean-louis Frossard, Christian Felley, Marie-anne Brundler, Pietro Majno, Antoine HadengueAbstract:Occasional side-effects of Transcatheter Arterial Chemoembolization therapy in hepatocellular carcinoma are essentially related to tissue necrosis. We report the case of a patient with hepatocellular carcinoma who experienced an acute common bile duct obstruction a few weeks after such a procedure, in the absence of obvious biliary tract invasion. An endoscopic sphincterotomy relieved the obstruction. At histology, the intra-biliary material was identified as a fragment of hepatocellular carcinoma. We discuss the causes of obstructive jaundice in the setting of hepatocellular carcinoma as well as in the specific situation of Transcatheter Arterial Chemoembolization therapy.
Long-hua Chen - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with Transcatheter Arterial Chemoembolization for hepatocellular carcinoma.
World journal of gastroenterology, 2004Co-Authors: Li Liu, Long-hua ChenAbstract:Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with Transcatheter Arterial Chemoembolization for hepatocellular carcinoma
